YPEL1 Inhibits Development of Gemcitabine Resistance in NK / T Cell Lymphomas
These findings suggest that YPEL1 exhibits the potential for being used as a target for NK / T cell lymphoma treatment.
Authors
- Siyu Qian (ORCID: https://orcid.org/0000-0002-4877-4537)
- Qingjiang Chen
- Yue Zhang (ORCID: https://orcid.org/0000-0002-4147-3838)
- Mingzhi Zhang
- Wang Miao (ORCID: https://orcid.org/0000-0003-2289-2962)
- Xudong Zhang (ORCID: https://orcid.org/0009-0002-8631-3632)
Institutions
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Current Cancer Drug Targets
- Published
- 2025-03-17
- DOI
- https://doi.org/10.2174/0115680096328745250122231110
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00